Trinity Biotech (TRIB) Operating Margin (2009 - 2024)
Trinity Biotech (TRIB) posted quarterly Operating Margin of 72.61% for Q4 2024, down 4446.0% year-on-year from 1.67% in Q1 2024, and down 330.07% on a QoQ basis from 16.88% in Q3 2024.
Trinity Biotech (TRIB) Operating Margin (2009 - 2024) Analysis & Trends
Trinity Biotech (TRIB) has reported Operating Margin for 16 consecutive years, with 72.61% the latest figure, recorded in Q4 2024.
- Quarterly Operating Margin fell 4446.0% year-over-year to 72.61% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 34.38% (up 1321.0% YoY) and the FY2025 annual result came in at 36.06%, down 168.0% from the prior year.
- Operating Margin fell to 72.61% in Q4 2024 per TRIB's latest filing, from 16.88% in the prior quarter.
- Over the last five years, Operating Margin for TRIB reached as high as 28.38% in Q3 2020 and fell as low as 106.86% in Q2 2023.
- A 5-year average of 17.79% and a median of 14.44% in 2022 frame the typical range for Operating Margin.
- Annual changes were most pronounced in 2023 — Operating Margin sank 9486 bps — and 2024, when it soared 8129 bps.
- Year by year, Operating Margin stood at 27.67% in 2020, then plunged by 90 bps to 2.88% in 2021, then tumbled by 1899 bps to 51.87% in 2022, then soared by 46 bps to 28.14% in 2023, then slumped by 158 bps to 72.61% in 2024.
- According to Business Quant data, Operating Margin over the past three periods registered 72.61%, 16.88%, and 25.58% for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 12.05% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 15.55% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 19.10% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 21.16% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 28.97% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 21.42% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 6.17% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 10.04% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Trinity Biotech | 93,750.00 | -5.04 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -72.61% |
| Sep 30, 2024 | -16.88% |
| Jun 30, 2024 | -25.58% |
| Mar 31, 2024 | -20.68% |
| Dec 31, 2023 | -28.14% |
| Sep 30, 2023 | -30.66% |
| Jun 30, 2023 | -106.86% |
| Mar 31, 2023 | -26.43% |
| Dec 31, 2022 | -51.87% |
| Sep 30, 2022 | -51.78% |
| Jun 30, 2022 | -12.00% |
| Mar 31, 2022 | -7.76% |
| Dec 31, 2021 | 2.88% |
| Sep 30, 2021 | 12.58% |
| Jun 30, 2021 | 0.84% |
| Mar 31, 2021 | 12.03% |
| Dec 31, 2020 | 27.67% |
| Sep 30, 2020 | 28.38% |
| Jun 30, 2020 | 3.13% |
| Mar 31, 2020 | 7.99% |